Discontinuation of antithrombotic therapy for a year or more in patients with continuous-flow left ventricular assist devices.
The recommended anticoagulation regimen during continuous-flow axial left ventricular assist device (LVAD) support is aspirin and warfarin with a targeted international normalized ratio of 2.0-3.0. We report two patients in whom recurrent gastrointestinal bleeding during LVAD support necessitated discontinuation of this anti-thrombotic regimen for a year or more. Despite this, neither patients developed thrombotic complications during 29 patient-months of follow-up. An acquired von Willebrand factor (VWF) abnormality reflected by the absence or decreased abundance of the highest molecular weight multimers was demonstrated in both patients. The gold standard test for platelet function, light transmission platelet aggregometry was measured in one patient and was normal, indicative that the predominant abnormality in the coagulation profile of these patients is an acquired VWF syndrome. Clinical trials are required to address the question whether it is safe to discontinue anticoagulation in LVAD patients with acquired VWF abnormalities.
Pereira
Naveen L
NL
Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, 200 First Street S.W., Rochester, MN 55905, USA. pereira.naveen@mayo.edu
Chen
Dong
D
Kushwaha
Sudhir S
SS
Park
Soon J
SJ
D000368:Aged; D009202:Cardiomyopathies / Q000601:surgery*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006471:Gastrointestinal Hemorrhage / Q000209:etiology* / Q000628:therapy; D006353:Heart-Assist Devices / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*; D028761:Withholding Treatment; D014842:von Willebrand Diseases / Q000209:etiology
D005343:Fibrinolytic Agents